[
  {
    "ts": "2026-02-19T05:37:49+00:00",
    "headline": "5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q4 Earnings Call",
    "summary": "Vertex Pharmaceuticals delivered fourth quarter results that outpaced Wall Street's revenue expectations, driven by continued expansion in cystic fibrosis therapies and early contributions from recently launched products in hematology and pain management. Management pointed to disciplined commercial execution and progress in diversifying the revenue base as key themes. CEO Reshma Kewalramani highlighted, “We are well positioned to deliver on the significant opportunities in front of us and drive",
    "url": "https://finance.yahoo.com/news/5-insightful-analyst-questions-vertex-053749023.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "77497bb5-f34e-3c26-93fa-3a6f3dfe14ef",
      "content": {
        "id": "77497bb5-f34e-3c26-93fa-3a6f3dfe14ef",
        "contentType": "STORY",
        "title": "5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q4 Earnings Call",
        "description": "",
        "summary": "Vertex Pharmaceuticals delivered fourth quarter results that outpaced Wall Street's revenue expectations, driven by continued expansion in cystic fibrosis therapies and early contributions from recently launched products in hematology and pain management. Management pointed to disciplined commercial execution and progress in diversifying the revenue base as key themes. CEO Reshma Kewalramani highlighted, “We are well positioned to deliver on the significant opportunities in front of us and drive",
        "pubDate": "2026-02-19T05:37:49Z",
        "displayTime": "2026-02-19T05:37:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "VRTX Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l6Y31wu10RiElUns.3mORA--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Qe_uhCRKlCGgByoENi3GZg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/5-insightful-analyst-questions-vertex-053749023.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-insightful-analyst-questions-vertex-053749023.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-19T12:16:08+00:00",
    "headline": "CRISPR Therapeutics touts zugo-cel CAR-T gains, eyes autoimmune expansion at Citi oncology summit",
    "summary": "CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline during Citi’s Virtual Oncology Leadership Summit, emphasizing updates on its allogeneic CAR-T program zugo-cel (formerly CTX112) and outlining a strategy that includes combinati",
    "url": "https://www.marketbeat.com/instant-alerts/crispr-therapeutics-touts-zugo-cel-car-t-gains-eyes-autoimmune-expansion-at-citi-oncology-summit-2026-02-19/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "eb1cd0ab-088f-37b9-a4e6-291186980207",
      "content": {
        "id": "eb1cd0ab-088f-37b9-a4e6-291186980207",
        "contentType": "STORY",
        "title": "CRISPR Therapeutics touts zugo-cel CAR-T gains, eyes autoimmune expansion at Citi oncology summit",
        "description": "",
        "summary": "CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline during Citi’s Virtual Oncology Leadership Summit, emphasizing updates on its allogeneic CAR-T program zugo-cel (formerly CTX112) and outlining a strategy that includes combinati",
        "pubDate": "2026-02-19T12:16:08Z",
        "displayTime": "2026-02-19T12:16:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/cf4691a045e077a356771fb4234f4817",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "CRISPR Therapeutics logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/R4vSX.hqaAJoqbI1io5tIw--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/cf4691a045e077a356771fb4234f4817.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YupJrDgMAdtmnmkIYdyFkA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/cf4691a045e077a356771fb4234f4817.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/crispr-therapeutics-touts-zugo-cel-car-t-gains-eyes-autoimmune-expansion-at-citi-oncology-summit-2026-02-19/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/crispr-therapeutics-touts-zugo-cel-121608154.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRSP"
            },
            {
              "symbol": "C"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]